Linus Health, an AI-driven brain health company focused on early detection of cognitive impairment and personalised intervention, will present new evidence validating its digital cognitive assessment tools at the 18th annual Clinical Trials on Alzheimer’s Disease (CTAD) conference, taking place Dec. 1-4 in San Diego. The company’s research highlights the potential of AI-enabled assessments to identify early disease indicators, improve patient-centered outcomes, and accelerate clinical trial recruitment and screening.

At CTAD 2025, Linus Health will present five scientific posters under the “Clinical Trials: Cognitive and Functional Endpoints” and “Cognitive Assessment and Clinical Trials” sessions. Three posters focus on the electronic Person-Specific Outcome Measure (ePSOM), which captures outcomes meaningful to people living with Alzheimer’s disease. Two additional posters highlight the Digital Clock and Recall (DCR) and Digital Assessment of Cognition (DAC) tools, demonstrating their ability to identify Alzheimer’s disease risk and treatment eligibility accurately.

Poster highlights include:

• P313: ePSOM’s feasibility, cultural adaptability, and high acceptability in Japanese memory clinics, supporting its use in multinational trials.

• P315: ePSOM’s ability to track self-reported confidence in personal priorities, showing sensitivity to early cognitive change beyond traditional measures.

• P340: The three-minute DCR assessment identifies patients likely to be amyloid-positive and treatment-eligible, streamlining recruitment and clinical workflows.

• P343: DAC predicts plasma p-tau217 status in seven minutes, enabling remote-ready, scalable screening for Alzheimer’s pathology in cognitively unimpaired individuals.

• P306: ePSOM captures outcomes that reflect what matters most to patients, validating its use as a patient-centered endpoint aligned with evolving regulatory guidance.

“Digital assessments that can both detect subtle cognitive changes and reflect what truly matters to patients are critical to advancing clinical research and care,” John Showalter, MD, MSIS, chief operating officer of Linus Health, said. “Our findings presented at CTAD will show how our AI-enhanced tools can identify Alzheimer’s risk earlier and accelerate the pipeline for disease-modifying treatments by improving trial efficiency and diversity.”

In addition, Linus Health’s manuscript, “Concurrent detection of cognitive impairment and amyloid positivity with a multimodal machine learning-enabled digital cognitive assessment,” has been accepted for publication in Alzheimer’s Research & Therapy. The study demonstrates that the tablet-based DCR assessment can accurately detect cognitive impairment and estimate amyloid positivity in three minutes, offering a scalable approach for early identification of Alzheimer’s-related brain changes.

Linus Health will host meetings with life sciences partners throughout the conference to discuss how its tools can improve recruitment, strengthen outcome measures, and generate real-world evidence. Attendees can also visit Linus Health’s virtual booth to learn more.

“CTAD brings together leading minds focused on Alzheimer’s research and innovation,” David Bates, PhD, CEO and co-founder of Linus Health, said. “Our work presented here demonstrates how technology-enabled, person-centered assessments can support early detection, appropriate selection to reduce costs and enhance trial outcomes, and ultimately lead to better brain health for people worldwide.”